Assertio Inc. (ASRT)
NASDAQ: ASRT
· Real-Time Price · USD
0.63
0.02 (3.28%)
At close: May 12, 2025, 9:42 AM
Assertio Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| CAMBIA Revenue | 5.56M | 8.07M | 100.34M | 60.56M | 31.68M | 108.81M | 129.97M |
| CAMBIA Revenue Growth | -31.15% | -91.96% | +65.69% | +91.13% | -70.88% | -16.28% | n/a |
| INDOCIN Products Revenue | 26.76M | 2.43M | 11.15M | -985K | 9.1M | 2.08M | 26.06M |
| INDOCIN Products Revenue Growth | +999.92% | -78.18% | -1231.78% | -110.82% | +336.71% | -92.00% | n/a |
| Otrexup Revenue | 8.84M | 87.22M | 155.12M | 109.42M | 93.5M | n/a | n/a |
| Otrexup Revenue Growth | -89.86% | -43.77% | +41.77% | +17.03% | n/a | n/a | n/a |
| Product and Service, Other Revenue | 2.1M | 12.03M | 4.67M | 5.03M | 1.52M | n/a | n/a |
| Product and Service, Other Revenue Growth | -82.54% | +157.35% | -7.10% | +231.14% | n/a | n/a | n/a |
| Product Revenue | 120.85M | 185K | 2.4M | 2.58M | 11.08M | n/a | n/a |
| Product Revenue Growth | +65223.78% | -92.30% | -6.82% | -76.72% | n/a | n/a | n/a |
| Product, Other Revenue | 1.52M | 149.45M | 9.11M | 8.68M | n/a | n/a | n/a |
| Product, Other Revenue Growth | -98.98% | +1540.52% | +5.00% | n/a | n/a | n/a | n/a |
| Royalties And Milestones Revenue | 2.01M | 1.42M | n/a | n/a | n/a | n/a | n/a |
| Royalties And Milestones Revenue Growth | +42.19% | n/a | n/a | n/a | n/a | n/a | n/a |
| SPRIX Nasal Spray Revenue | 7.62M | 9.15M | n/a | n/a | n/a | n/a | n/a |
| SPRIX Nasal Spray Revenue Growth | -16.68% | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 21.42M | 16.73M | 18.39M | 18.42M | 23.46M | 21M | 16.77M | 16.9M | 13.71M | 11.9M | 10.54M | 10.64M | 13.28M | 9.31M | 26.23M | 7.73M | 21.27M | 25.75M | 28.13M | 27.31M | 22.95M | 36.12M | 24.75M | 25.05M | 25.47M | 33.41M | 31.31M | 29.03M | 48.32M | 48.85M | 50.01M | 48.52M | 48.46M | 51.57M | 51.9M | 52.56M | 58.34M | 49.06M | 57.41M | 34.54M |
| Selling, General, and Administrative Revenue Growth | +28.04% | -9.02% | -0.21% | -21.48% | +11.71% | +25.25% | -0.79% | +23.33% | +15.18% | +12.87% | -0.89% | -19.88% | +42.56% | -64.50% | +239.39% | -63.66% | -17.38% | -8.48% | +2.99% | +19.02% | -36.46% | +45.90% | -1.16% | -1.66% | -23.77% | +6.71% | +7.84% | -39.91% | -1.09% | -2.32% | +3.07% | +0.12% | -6.03% | -0.63% | -1.25% | -9.90% | +18.90% | -14.53% | +66.20% | n/a |
| Research and Development Revenue | 1.29M | 1M | 798K | 733K | 1.02M | 1.32M | 503K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 230K | 1.32M | 1.63M | 1.04M | 5.58M | 1.48M | 1.26M | 1.79M | 2.21M | 2.13M | 2.18M | 1.53M | 26.16M | 1.76M | 5.61M | 5.08M | 9.15M | 10.41M | 7.12M | 5.95M | 61.24M | 4.63M | 4.71M | 1.86M |
| Research and Development Revenue Growth | +27.96% | +25.94% | +8.87% | -28.42% | -22.19% | +161.63% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | -82.52% | -19.07% | +56.20% | -81.33% | +277.71% | +16.86% | -29.56% | -18.76% | +3.76% | -2.43% | +42.67% | -94.16% | +1385.46% | -68.63% | +10.42% | -44.46% | -12.08% | +46.32% | +19.62% | -90.29% | +1222.96% | -1.80% | +153.71% | n/a |